Dr. Matthew Prime

Roche Diagnostics Information Solutions

Dr. Matt Prime is the Global Medical Director for Roche Diagnostics Information Solutions (DIS) based in Basel, Switzerland. Dr. Prime graduated from University College London in 2005 with a medical degree and a bachelor’s
degree in tumor biology. He spent 12 years in clinical practice in the United Kingdom working as a trauma & orthopedic surgeon. In 2013 he co-developed PathPoint TM – a patient care coordination system - to help frontline
trauma surgeons better organize the care of patients. This solution has now been widely implemented across the NHS and in 2017, in recognition of his work in digital healthcare he became an NHS clinical entrepreneurship
fellow.
In 2014 he took up an academic appointment at Imperial College London, within the Institute of Global Health Innovation (IGHI) led by Professor the Lord Darzi of Denham, former Under-Secretary of State at the UK Department of Health. His PhD focused on the enablers and barriers to innovation diffusion in the healthcare sector, with specific reference to innovation originating in low or middle-income countries. Between 2014-17 he was the clinical advisor to the HELIX Center for Design in Healthcare, a design studio in the heart of St Mary’s
Hospital in London, applying design-thinking to develop patient-centered digital healthcare solutions.

dont miss

Personalized healthcare: Leveraging data to improve patient care through clinical decision support in oncology

Roche, known for its biopharmaceuticals and in-vitro diagnostics solutions has entered the field of Clinical Decision Support by building a portfolio of software products.
Learn how the NAVIFY ® Decision Support portfolio leverages excellence in clinical workflow, advanced analytics and innovative strategic partnerships to bring together diagnostic, real-world data to deliver personalized healthcare.

EVEN MORE SEMINARS

  • Lucinda Billingham: Speaking at the Oncology Convention

    Lucinda Billingham
    University of Birmingham - Cancer Research Clinical Trials Unit

    National Lung Matrix Trial: testing multiple novel targeted treatments

  • Prof Ingunn Holen: Speaking at the Oncology Convention

    Prof Ingunn Holen
    Department of Oncology and Metabolism, University of Sheffield, UK

    Tumour cell dormancy and breast cancer relapse

  • Professor Jayant Vaidya: Speaking at the Oncology Convention

    Professor Jayant Vaidya
    University College London

    Targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer

  • Professor Robert Thomas: Speaking at the Oncology Convention

    Professor Robert Thomas
    Bedford and Addenbrooke's Cambridge University Hospitals

    Evidence based lifestyle strategies after cancer - a research review

  • Professor Noel Clarke: Speaking at the Oncology Convention

    Professor Noel Clarke
    The Christie and Salford Royal Hospitals, Manchester UK

    Improving Prostate Cancer Outcomes Through Cancer Trials